ArticleScientific reports2026
A novel innovation using modified platelet-rich plasma (mPRP) for preventing urethral stricture recurrence in a rabbit model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urethroplasty is the gold standard for urethral stricture but is limited by technical complexity and surgeon expertise. Thus, urethrotomy and dilatation remain common despite high recurrence rates (40-60%) from fibrosis. Platelet-rich plasma (PRP), a regenerative therapy, promotes tissue healing but contains transforming growth factor-β1 (TGF-β1), which may worsen fibrosis. To overcome this, a modified PRP (mPRP) was developed by neutralizing TGF-β1, aiming to enhance healing while reducing fibrosis and recurrence in urethral stricture management. An experimental study was conducted using New Zealand White rabbits (Oryctolagus cuniculus). A urethral stricture model was induced through surgical urethral injury followed by TGF-β injection. Animals were treated with either standard PRP or mPRP. Outcomes were assessed through immunohistochemistry (IHC) and retrograde urethrography. Collagen thickness decreased in the PRP group (16.2 ± 2.4 µm; p < 0.05) and further in the mPRP group (11.38 ± 1.46 µm; p < 0.05). IHC revealed lower collagen type III levels in the mPRP group (3.0 ± 1.0) compared with PRP (6.8 ± 0.83), yielding a higher collagen I:III ratio (1:2.6 vs. 1:1.36). Urethrography demonstrated a wider lumen (2.72 ± 0.14 mm) and shorter stricture length (0.60 ± 0.63 cm) in the mPRP group compared to PRP (2.41 ± 0.10 mm and 2.48 ± 0.16 cm; p < 0.05). mPRP effectively reduces fibrosis and inhibits stricture recurrence, as evidenced by decreased collagen expression and improved urethral lumen dimensions, supporting its potential as an adjunctive therapy for urethral stricture management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.